Guardant Health, Inc.
GH
주식 순위
#1077
Guardant Health, Inc., established in Redwood City, California, in 2011, is a... Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
주가
$162.03
시가총액
$21.74B
변동 (1일)
2.63%
변동 (1년)
130.82%
국가
US
거래 Guardant Health, Inc. (GH)
카테고리
Healthcare
Guardant Health, Inc. (GH)의 매출
Jun 2026 기준 매출 TTM: $1.18B
Guardant Health, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $1.18B입니다. 2023년에 회사는 $563.95M의 수익을 올렸으며 이는 2022년의 $449.54M 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Guardant Health, Inc.의 수익 기록 (2016 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $1.18B | 60.09% |
| 2024 | $739.02M | 31.04% |
| 2023 | $563.95M | 25.45% |
| 2022 | $449.54M | 20.31% |
| 2021 | $373.65M | 30.32% |
| 2020 | $286.73M | 33.75% |
| 2019 | $214.38M | 136.52% |
| 2018 | $90.64M | 81.85% |
| 2017 | $49.84M | 97.40% |
| 2016 | $25.25M | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $46.34B | 3,816.47% |
US
|
|
| $25.11B | 2,022.13% |
US
|
|
| $2.71B | 128.81% |
US
|
|
| - | - |
CN
|
|
| $7.37B | 523.11% |
US
|
